Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia Meeting Abstract


Authors: Bennison, C.; Durno, N.; Sail, K.; Alexiou, D.; Mato, A.; Eyre, T.; Follows, G.
Abstract Title: Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia
Meeting Title: 18th International Workshop on Chronic Lymphocytic Leukemia
Journal Title: Leukemia and Lymphoma
Volume: 61
Issue: Suppl. 1
Meeting Dates: 2019 Sept 20-23
Meeting Location: Edinburgh, United Kingdom
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2020-01-01
Start Page: 153
End Page: 155
Language: English
ACCESSION: WOS:000534385400111
PROVIDER: wos
PUBMED: 32436402
DOI: 10.1080/10428194.2020.1732667
Notes: Meeting Abstract: 2070 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Anthony R Mato
    235 Mato